SELLAS Life Sciences Group (NASDAQ: SLS) insider transactions
In the twelve months to 10 November 2026, executives and directors of SELLAS Life Sciences Group reported 0 open-market sales and 1 open-market purchase of 63,400 shares ($100,806), by 1 person, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 16 June 2026 | Stergiou Angelos M. | President and CEO | Grant or award | +1,065,000 | — | 1,759,183 | Form 4 |
| 7 January 2026 | Wasman Jane | Director | Grant or award | +50,000 | — | 92,900 | Form 4 |
| 7 January 2026 | Kalin Katherine Bach | Director | Grant or award | +50,000 | — | 154,400 | Form 4 |
| 7 January 2026 | Burns John Thomas | CFO | Grant or award | +300,000 | — | 554,327 | Form 4 |
| 7 January 2026 | Cicic Dragan | SVP, Chief Development Officer | Grant or award | +300,000 | — | 557,805 | Form 4 |
| 7 January 2026 | Scheinberg David A | Director | Grant or award | +50,000 | — | 73,082 | Form 4 |
| 7 January 2026 | Van Nostrand Robert L | Director | Grant or award | +50,000 | — | 82,900 | Form 4 |
| 7 January 2026 | Varian John | Director | Grant or award | +50,000 | — | 72,900 | Form 4 |
| 3 December 2025 | Stergiou Angelos M. | President and CEO | Other | −187,066 | $1.50 | 686,966 | Form 4 |
| 3 December 2025 | Burns John Thomas | CFO | Other | −58,592 | $1.50 | 254,327 | Form 4 |
| 3 December 2025 | Cicic Dragan | SVP, Chief Development Officer | Other | −63,800 | $1.50 | 257,805 | Form 4 |
| 19 November 2025 | Kalin Katherine Bach | Director | Open-market purchase | +63,400 | $1.59 | 104,400 | Form 4 |
| 12 June 2025 | Van Nostrand Robert L | Director | Open-market purchase | +10,000 | $1.48 | 20,400 | Form 4 |
| 30 May 2025 | Wasman Jane | Director | Open-market purchase | +20,000 | $1.69 | 30,400 | Form 4 |
| 22 May 2025 | Kalin Katherine Bach | Director | Open-market purchase | +20,000 | $1.80 | 41,000 | Form 4 |
| 10 January 2025 | Cicic Dragan | SVP, Chief Development Officer | Grant or award | +113,000 | — | 228,328 | Form 4 |
| 10 January 2025 | Cicic Dragan | SVP, Chief Development Officer | Grant or award | +81,300 | — | 309,628 | Form 4 |
| 10 January 2025 | Varian John | Director | Grant or award | +12,500 | — | 22,900 | Form 4 |
| 10 January 2025 | Kalin Katherine Bach | Director | Grant or award | +12,500 | — | 21,000 | Form 4 |
| 10 January 2025 | Van Nostrand Robert L | Director | Grant or award | +12,500 | — | 22,900 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the SELLAS Life Sciences Group page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.